Next Generation Sequencing (NGS) Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Next Generation Sequencing (NGS) Market size was estimated at USD 12,990 million in 2024 and is projected to reach USD 31,910.4 million in 2031 at a CAGR of 13.7 % during the forecast period 2025-2031.

Next Generation Sequencing (NGS) refers to a set of advanced technologies that allow for rapid and high-throughput sequencing of DNA and RNA, enabling researchers to decode genetic material more efficiently and cost-effectively than traditional methods. NGS encompasses various techniques that facilitate deep sequencing, such as whole genome sequencing, exome sequencing, and transcriptome sequencing, allowing for detailed analyses of genetic variations, mutations, and gene expression profiles. This technology has revolutionized genomic research, clinical diagnostics, and personalized medicine, offering a powerful tool for understanding complex biological processes and diseases.

The scope of the NGS market extends across a wide range of applications, including genomics, oncology, infectious diseases, and reproductive health. In genomics, NGS is crucial for identifying genetic disorders and discovering new biomarkers. In oncology, it is used for cancer diagnostics and developing targeted therapies by detecting specific mutations in tumor cells. NGS is also employed in microbiology for pathogen detection and in the field of agriculture for improving crop traits and livestock breeding. The adoption of NGS in clinical diagnostics and personalized medicine is rapidly growing, with several NGS-based tests already approved for use in medical practice, reflecting the broad potential of this technology.

The NGS market is primarily driven by advances in sequencing technologies that continue to improve accuracy, speed, and affordability. The decreasing cost of sequencing has been a significant factor in the widespread adoption of NGS, enabling both academic researchers and healthcare professionals to leverage it for routine testing and studies. Additionally, the growing prevalence of chronic diseases, particularly cancer, and the increasing demand for precision medicine have led to a surge in NGS applications in clinical settings. Furthermore, the availability of user-friendly platforms, along with improved bioinformatics tools, is enhancing the accessibility and efficiency of NGS, making it easier for professionals to interpret vast amounts of sequencing data.

Key trends influencing the NGS market include the growing integration of NGS with artificial intelligence (AI) and machine learning (ML) for enhanced data analysis, as well as the rise of liquid biopsy, which allows for non-invasive detection of genetic mutations and cancer biomarkers. Another emerging trend is the focus on improving the accuracy and sensitivity of sequencing techniques to detect rare mutations and genetic variants. Additionally, the increasing emphasis on personalized medicine is expected to further propel the demand for NGS, as it allows for more tailored therapeutic approaches based on an individual's genetic makeup. As the technology continues to evolve, NGS is expected to play a pivotal role in advancing precision medicine and transforming healthcare.

Delvens Industry Expert's Standpoint

Experts in the Next Generation Sequencing (NGS) Market highlight several key trends driving growth and innovation. Next Generation Sequencing (NGS) is a transformative technology that enables rapid, high-throughput sequencing of DNA and RNA, revolutionizing genomics, clinical diagnostics, and personalized medicine. It has broad applications across fields like oncology, infectious diseases, and agriculture, allowing for detailed genetic analysis and mutation detection. The market is driven by advances in sequencing technologies that reduce costs, improve accuracy, and expand accessibility, alongside the increasing demand for precision medicine and targeted therapies. Key trends include the integration of AI for data analysis, the rise of non-invasive liquid biopsy, and a focus on enhancing sequencing accuracy. NGS is expected to continue shaping the future of healthcare by enabling more personalized and effective treatments.

Market Portfolio

Key Findings

• The targeted sequencing and resequencing technology segment is growing in tandem with the broader expansion of whole genome sequencing (WGS). As WGS generates vast amounts of data, there is a corresponding need for targeted analysis of specific genes and genetic expressions. Companies like Illumina and Pacific Biosciences offer specialized solutions, such as gene panels and targeted resequencing platforms, which are pivotal in areas like cancer diagnostics. These technologies are expected to remain essential, particularly in molecular cancer diagnostics, where detecting genetic mutations in both blood cancers and solid tumors is crucial.

• The consumables segment leads the market, driven by the recurrent demand for consumables in both commercial and research applications of NGS. These consumables, including sample preparation kits and target enrichment kits, are vital for various diagnostic and research purposes, such as cancer research and genomic sequencing. Key players in the market, like PerkinElmer, continue to innovate by introducing new products, such as advanced sample preparation kits, further supporting market growth. The increasing adoption of NGS technologies by pharmaceutical companies and research institutes ensures a consistent demand for consumables.

• In the application space, the oncology segment stands out due to the increasing need for advanced technologies to study cancer and tumor dynamics. The use of NGS in cancer research, particularly for DNA and RNA sequencing, epigenetics, and chromosomal abnormalities, is accelerating the growth of this segment. Genetic testing services, such as Myriad’s myRisk product, and research collaborations, like those between Merus N.V. and prominent cancer centers, are central to ongoing advancements in oncology applications. This segment’s growth is closely tied to the need for more personalized and precise cancer treatments.

• Sequencing is the most significant phase within the NGS workflow and continues to dominate the market. NGS sequencing systems are integral for accurate liquid handling, tube and microplate management, and overall process automation. These systems help streamline workflows, allowing researchers to focus more on analyzing the data than managing the sequencing process itself. As the demand for precision and efficiency grows, sequencing systems are becoming increasingly critical in both research and clinical settings, contributing to the overall market expansion.

• The academic research segment holds the largest share in the end-use category, with universities and research institutions extensively utilizing NGS solutions for a variety of studies. The availability of scholarships for PhD projects focused on NGS and the increasing prevalence of bioinformatics workshops and hands-on courses are expected to further drive growth in this segment. As NGS continues to be a central tool in cutting-edge research, especially in genomics and disease-related studies, the academic research segment will continue to see strong demand for NGS technologies.

• The clinical research segment is also poised for significant growth, particularly in cancer research. NGS applications in discovering cancer-related genes, studying tumor heterogeneity, and identifying alterations involved in tumorigenesis are key drivers of growth in this area. With companies like Illumina and Thermo Fisher Scientific offering advanced clinical research solutions, the segment is expected to expand rapidly over the forecast period.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as rising demand for precision medicine, technological advancements, decreasing sequencing costs, government initiatives and funding, expanding clinical applications, growing oncology applications, advancements in bioinformatics, increasing adoption in drug development, integration into public health initiatives, enhanced consumer awareness and acceptance have triggered the next generation sequencing (NGS) market in the region.

Regional Analysis

North America to Dominate the Market

• North America led the NGS market with a dominant share of approximately 50%. This growth is driven by the presence of numerous clinical laboratories utilizing NGS for genetic testing services. Additionally, high levels of R&D investment, along with a robust healthcare research framework, are contributing to the development of WGS in the region. These factors are expected to play a significant role in the continued expansion of the North American NGS market.

• The Asia Pacific region is anticipated to be the fastest-growing market, fuelled by significant advancements in China and Japan regarding the integration of NGS technologies. Additionally, the development of healthcare, R&D, and clinical frameworks in emerging economies such as India and Australia is creating abundant growth opportunities for the NGS market in the region.

• The UK Next Generation Sequencing market is expected to grow in line with the broader European market, driven by the increasing development of companion diagnostics and the establishment of molecular diagnostic facilities by leading market players. Strategic alliances between European and Eastern markets are also expected to boost the growth of the next-generation sequencing market in the region.

Competitive Landscape

• Illumina
• F. Hoffman-La Roche Ltd.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Oxford Nanopore Technologies
• PierianDx
• Genomatix GmbH
• DNASTAR, Inc.
• Perkin Elmer, Inc.
• Eurofins GATC Biotech GmbH
• BGI.

Recent Developments

• In May 2024, Oxford Nanopore Technologies partnered with Twist Bioscience to introduce a new Pharmacogenomics Beta Programme. This long-read pharmacogenomics solution, intended for research use, aims to deliver clear genetic results through a streamlined, end-to-end workflow, from sample preparation to pharmacogenomics star allele calling.

• In September 2023, PacBio unveiled a collaboration with Hamilton, Integra, Revvity, and Tecan to develop fully automated protocols for preparing samples to be sequenced on the Revio and Sequel II and IIe systems.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Next Generation Sequencing (NGS) Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope